A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples